Clera Antipsychotic Science

clerainc
26 Aug 201003:23

Summary

TLDRThe script reveals a surprising discovery in neuroscience: all antipsychotic medications target a specific region in the brain, the caudate putamen, which is rich in dopamine type 2 receptors. These receptors are crucial for motor control and are also linked to psychological functions. The script delves into the molecular interaction between dopamine and antipsychotics like haloperidol and olanzapine, highlighting how they block dopamine receptors, leading to varying degrees of efficacy and side effects, including Parkinsonism and tardive dyskinesia.

Takeaways

  • 🧠 The discovery of a common target in the brain for all antipsychotics was a significant revelation, contrary to the belief that they acted in various parts of the brain.
  • 💊 Antipsychotic medications primarily target the type 2 dopamine receptor, which is abundant in the caudate putamen region of the basal ganglia, responsible for motor control.
  • 🤔 Dopamine type 2 receptors are also found in areas associated with psychological functions, such as the cingulate gyrus, cerebral cortex, and nucleus accumbens.
  • 🔍 At the molecular level, dopamine is released in pulses and binds to its receptors rapidly, with antipsychotics like haloperidol blocking this access and affecting dopamine transmission.
  • 🆚 There is a competitive interaction between dopamine and antipsychotic drugs for receptor binding, with tightly bound drugs like haloperidol winning the competition.
  • 💊 Haloperidol is a long-acting drug, with a dose of 10 milligrams lasting for days, which is beneficial for controlling psychotic symptoms but can lead to accumulation and side effects over time.
  • 🚫 High blockade by haloperidol can cause extrapyramidal symptoms, such as Parkinsonism, elevated prolactin levels, amenorrhea, and tardive dyskinesia.
  • 💊 Olanzapine is another antipsychotic effective at lower doses but can produce Parkinsonism and a risk of tardive dyskinesia at higher doses.
  • 📈 The risk of weight gain is associated with olanzapine use, which is an important consideration when prescribing this medication.
  • 🔄 The script emphasizes the importance of understanding the molecular interactions of antipsychotics with the brain's dopamine system to manage their therapeutic effects and side effects effectively.

Q & A

  • What was the surprising discovery about the common target of antipsychotics in the brain?

    -The surprising discovery was that all antipsychotics have a common target in the brain, which is the Spartan in the brain. This was unexpected as it was previously believed that antipsychotics acted on many parts of the brain and various proteins and receptors.

  • How many types of dopamine receptors are there in the brain, and which one is targeted by antipsychotic medication?

    -There are five types of dopamine receptors in the brain. Antipsychotic medication specifically targets the type 2 receptor.

  • In which part of the brain are the type 2 dopamine receptors predominantly located, and what is its primary function?

    -Type 2 dopamine receptors are predominantly located in the caudate putamen in the basal ganglia of the brain, which is primarily responsible for motor control of the body, including the arms and legs.

  • Which brain regions are associated with psychological functions and also contain type 2 dopamine receptors?

    -The cingulate gyrus, the cerebral cortex, and the nucleus accumbens are brain regions associated with psychological functions that also contain type 2 dopamine receptors.

  • What happens at the molecular level when dopamine is released by nerve cells?

    -Dopamine is released by nerve cells at a rate of five times per second in great pulses. The molecule then travels to the receptor area, which is just 100 angstroms away, and binds to the receptor very quickly, potentially a million times a second.

  • How does haloperidol, an antipsychotic, affect the interaction between dopamine and its receptors?

    -Haloperidol blocks access to the receptor by dopamine, creating a competition between the drug and the dopamine molecule. In this competition, haloperidol, being tightly bound, usually wins, resulting in partial blocking of dopamine transmission.

  • What is the difference in the way olanzapine blocks the dopamine receptor compared to haloperidol?

    -While olanzapine also blocks the dopamine receptor, dopamine molecules can still out-compete some of the olanzapine, allowing for some modest transmission of dopamine.

  • How does the dosing of haloperidol affect its binding to the receptor and its duration in the body?

    -Haloperidol is a tightly bound drug that comes off slowly. A dose of 10 milligrams per patient per day can stay in the body for a day or two or more, which is beneficial for controlling psychotic symptoms.

  • What are the potential long-term effects of continuous daily dosing of haloperidol?

    -Continuous daily dosing of haloperidol can lead to an accumulation of the drug, causing tardive dyskinesia and extrapyramidal symptoms.

  • At what level of blockade by haloperidol does parkinsonism become a risk?

    -Parkinsonism becomes a risk when there is more than 80% blockade by haloperidol.

  • What are some side effects associated with olanzapine use?

    -Olanzapine can cause parkinsonism at doses above 20 or 30 milligrams per day, and there is a risk of tardive dyskinesia and weight gain.

Outlines

plate

This section is available to paid users only. Please upgrade to access this part.

Upgrade Now

Mindmap

plate

This section is available to paid users only. Please upgrade to access this part.

Upgrade Now

Keywords

plate

This section is available to paid users only. Please upgrade to access this part.

Upgrade Now

Highlights

plate

This section is available to paid users only. Please upgrade to access this part.

Upgrade Now

Transcripts

plate

This section is available to paid users only. Please upgrade to access this part.

Upgrade Now
Rate This

5.0 / 5 (0 votes)

Related Tags
AntipsychoticsDopamineBrainReceptorsPsychiatryNeuroscienceMolecularPharmacologyTardive DyskinesiaMedication